Patients with cancer are often treated with potentially cardiotoxic chemotherapeutics. Cardiotoxicity ranges from relatively benign arrhythmias to serious conditions such as myocardial ischemia/infarction, congestive heart failure, and cardiomyopathy. In spite of different diagnostic methods, with echocardiography as a gold standard, there is an intensive search for new diagnostic tools for the early detection of myocardial abnormalities. Available data suggest that the levels of circulating cardiomarkers can monitor the extent and severity of the myocardial damage. The role of routinely used cardiomarkers is controversial and limited in this setting. Natriuretic peptides have shown promising results in assessment and monitoring of both acute and late clinical and subclinical damage of the myocardium in association with chemotherapy. This article reviews clinical studies evaluating the role of natriuretic peptides in the early diagnosis of anthracycline cardiotoxicity, and their use in the management of cancer survivors.

Download full-text PDF

Source
http://dx.doi.org/10.3727/096504008784523621DOI Listing

Publication Analysis

Top Keywords

natriuretic peptides
12
peptides biochemical
4
biochemical markers
4
markers anthracycline
4
anthracycline cardiac
4
cardiac toxicity?
4
toxicity? patients
4
patients cancer
4
cancer treated
4
treated cardiotoxic
4

Similar Publications

Background: The phase angle (PhA) in bioelectrical impedance analysis (BIA) reflects the cell membrane integrity or body fluid equilibrium. We examined how the PhA aligns with previously known markers of acute heart failure (HF) and assessed its value as a screening tool.

Methods: PhA was measured in 50 patients with HF and 20 non-HF controls along with the edema index (EI), another BIA parameter suggestive of edema.

View Article and Find Full Text PDF

Background: Heart failure (HF) has become a public healthcare concern with significant costs to countries because of the aging world population. Acute heart failure (AHF) is a common condition faced frequently in emergency departments, and patients often present to hospitals with complaints of breathlessness. The patient must be evaluated with anamnesis, physical examination, blood, and imaging results to diagnose AHF.

View Article and Find Full Text PDF

High-sensitive cardiac troponin T and NT-proBNP are associated with the left ventricular apical thickness in apical hypertrophic cardiomyopathy.

Eur J Med Res

January 2025

Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China.

Background: Apical hypertrophic cardiomyopathy (AHCM) is a subtype of hypertrophic cardiomyopathy (HCM). The expression level of high-sensitive cardiac troponin T (hs-cTNT) and N-terminal pro-BNP (NT-proBNP) in AHCM patients, and these relationships between echocardiography parameters were still unclear.

Methods: We retrospectively screened AHCM patients between January 2019 and December 2021 in Zhongshan Hospital Fudan University.

View Article and Find Full Text PDF

Objective: To observe how cognitive behavioral intervention affects physical symptoms, B-type Natriuretic Peptide (BNP), Red Cell Distribution Width (RDW), and C-reactive Protein (CRP) in elderly patients with heart failure.

Methods: Convenient sampling method was used to select 98 elderly heart failure patients who visited our hospital from January 2022 to December 2020. Patients were divided into a control group and an observation group using the red and blue ball method, with 49 cases in each group.

View Article and Find Full Text PDF

Background: Plasma NT-proBNP (N-terminal pro-B-type natriuretic peptide) is commonly used to diagnose heart failure with preserved ejection fraction (HFpEF), but its diagnostic performance in the ambulatory/outpatient setting is unknown because previous studies lacked objective reference standards.

Methods: Among patients with chronic dyspnea, diagnosis of HFpEF or noncardiac dyspnea was determined conclusively by exercise catheterization in a derivation cohort (n=414), multicenter validation cohort 1 (n=560), validation cohort 2 (n=207), and a nonobese Japanese validation cohort 3 (n=77). Optimal NT-proBNP cut points for HFpEF rule out (optimizing sensitivity) and rule in (optimizing specificity) were derived and tested, stratified by obesity and atrial fibrillation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!